Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China
Source: View publication →
The HER3-directed antibody-drug conjugate ruzaltatug rezetecan significantly improved progression-free survival compared to standard chemotherapy in patients with EGFR-mutated advanced NSCLC who had progressed on prior EGFR-TKI therapy.
Key Findings
Study Design
Study Limitations
Clinical Significance
This trial validates ruzaltatug rezetecan, a novel HER3-directed antibody-drug conjugate, as a highly efficacious intervention in the difficult-to-treat post-TKI setting for EGFR-mutated NSCLC. By halving the risk of disease progression relative to standard platinum-pemetrexed chemotherapy with a manageable safety profile, it establishes a compelling new therapeutic avenue that directly addresses the limitations of current salvage treatments.
Historical Context
The standard first-line treatment for EGFR-mutated advanced NSCLC is a third-generation EGFR tyrosine kinase inhibitor (TKI), typically osimertinib. Despite durable initial responses, acquired resistance inevitably emerges. Historically, patients progressing on a third-generation TKI are relegated to platinum-based doublet chemotherapy, which typically yields a median PFS of roughly 4 to 5.5 months and substantial toxicity. The HERON-Lung01 trial represents a paradigm shift, successfully testing a targeted HER3-directed antibody-drug conjugate (ADC) in this space, keeping with a broader oncological trend of substituting conventional cytotoxic regimens with precision ADCs in pretreated disease states.
Guided Discussion
High-yield insights from every perspective
What is the mechanistic rationale for targeting HER3 with an antibody-drug conjugate (ADC) like ruzaltatug rezetecan in patients with EGFR-mutated non-small-cell lung cancer (NSCLC) who have developed resistance to EGFR tyrosine kinase inhibitors (TKIs)?
Key Response
HER3 is frequently co-expressed or upregulated in EGFR-mutated NSCLC and often acts as a bypass signaling pathway driving resistance to EGFR-TKIs like osimertinib. An ADC leverages this high HER3 expression to selectively deliver a potent cytotoxic payload directly into the tumor cells, thereby bypassing specific kinase domain resistance mutations that render TKIs ineffective.
For a patient with EGFR-mutated advanced NSCLC who progresses on first-line osimertinib without a targetable acquired mutation, how does the integration of ruzaltatug rezetecan alter the traditional treatment algorithm that typically relies on platinum-doublet chemotherapy?
Key Response
Historically, patients progressing on a 3rd-generation EGFR-TKI without a specific actionable resistance mechanism (such as MET amplification) are transitioned to platinum-pemetrexed chemotherapy. Ruzaltatug rezetecan offers a targeted, potentially more efficacious alternative, shifting the paradigm from broad cytotoxic chemotherapy to biomarker-directed payload delivery in the second-line setting, provided the toxicity profile is manageable.
Given the topoisomerase I inhibitor payload in ruzaltatug rezetecan, how should oncologists monitor and manage the anticipated unique toxicities, particularly interstitial lung disease (ILD), especially in patients with prior lung damage from EGFR-TKIs?
Key Response
ADCs with topoisomerase I payloads have a well-documented risk of potentially fatal ILD or pneumonitis. Prior EGFR-TKI use also carries an independent ILD risk, which may compound the danger. Fellows must recognize the need for vigilant monitoring with regular high-resolution CT scans and prompt discontinuation of the ADC and initiation of high-dose corticosteroids at the first sign of even grade 1 asymptomatic pneumonitis.
Should HER3 expression levels be routinely tested to select patients for ruzaltatug rezetecan, or is the ubiquitous expression of HER3 in EGFR-mutant NSCLC sufficient to justify its use empirically post-TKI progression?
Key Response
While HER3 is widely expressed in EGFR-mutated NSCLC, the necessity of a companion diagnostic remains a critical clinical and logistical question. Attendings must evaluate the trial data to see if low-HER3 expressers still derive significant benefit (potentially due to the bystander effect of the membrane-permeable payload) compared to chemotherapy, which dictates whether routine immunohistochemistry testing is a prerequisite or an unnecessary hurdle.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The HERON-Lung01 trial was conducted exclusively in China and utilized an open-label design. How might these factors introduce bias into the progression-free survival (PFS) endpoint, and what statistical or design mitigations are required for global regulatory approval?
Key Response
Open-label designs can lead to investigator bias in RECIST tumor assessments, making blinded independent central review (BICR) absolutely essential for validating the PFS endpoint. Furthermore, pharmacogenomic differences in drug metabolism or varying local standards of care in a single-country trial limit external validity, necessitating multiregional bridging studies to confirm consistent pharmacokinetics and efficacy for global approvals.
As a peer reviewer evaluating the interim analysis of this phase 3 trial, what specific data regarding the control arm's performance and the maturity of the overall survival (OS) data would you demand to ensure the PFS benefit is not merely an artifact of an underperforming control?
Key Response
Interim analyses for PFS can sometimes overestimate the true benefit. A rigorous reviewer would evaluate whether the control arm (chemotherapy) performed comparably to historical controls (e.g., yielding a PFS of 4.5 to 5.5 months). Additionally, they would flag the risk that early PFS gains might not translate to an OS benefit, and demand assurance that the control arm had access to adequate subsequent therapies to prevent artificial inflation of the experimental drug's relative efficacy.
Based on the HERON-Lung01 findings, what level of evidence does ruzaltatug rezetecan achieve for replacing platinum-based chemotherapy as the preferred second-line therapy in NCCN or ASCO guidelines for EGFR-mutated NSCLC post-osimertinib, and what specific data are required to assign it a Category 1 recommendation?
Key Response
Current guidelines recommend platinum-doublet chemotherapy for systemic progression post-osimertinib. To achieve a Category 1 recommendation to replace chemotherapy, the committee requires mature, statistically significant OS data, not just interim PFS. Furthermore, the committee must evaluate whether the rate of severe adverse events, particularly grade 3 or higher ILD, is sufficiently low to warrant a strong recommendation over the established safety profile of standard chemotherapy.
Clinical Landscape
Noteworthy Related Trials
AURA3
Tested
Osimertinib
Population
T790M-positive advanced NSCLC progressing after first-line EGFR-TKI therapy
Comparator
Platinum-based chemotherapy
Endpoint
Progression-free survival
MARIPOSA-2
Tested
Amivantamab plus chemotherapy
Population
EGFR-mutated advanced NSCLC progressing on osimertinib
Comparator
Chemotherapy
Endpoint
Progression-free survival
TROPION-Lung01
Tested
Datopotamab deruxtecan
Population
Previously treated advanced NSCLC including actionable genomic alterations
Comparator
Docetaxel
Endpoint
Progression-free survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis